Menu
Search
|

Menu

Close
X

Evofem Biosciences Inc EVFM.OQ (NASDAQ Stock Exchange Capital Market)

3.50 USD
+0.13 (+3.86%)
As of 2:29 AM IST
chart
Previous Close 3.37
Open 3.50
Volume 5,624
3m Avg Volume 16,672
Today’s High 3.53
Today’s Low 3.47
52 Week High 12.84
52 Week Low 1.80
Shares Outstanding (mil) 13.83
Market Capitalization (mil) 6.33
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-6.445
FY17
-46.255
FY16
-5.664
FY15
-18.903
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
0.97
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
0.00
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-80.14
15.05
Return on Equity (TTM)
vs sector
-90.12
16.62

EXECUTIVE LEADERSHIP

Saundra Pelletier
Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Justin File
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Maria Feldman
Vice President, Clinical Operations, Regulatory Affairs and Quality Assurance, Since 2016
Salary: --
Bonus: --
Alexander Fitzpatrick
General Counsel, Secretary, Since 2018
Salary: --
Bonus: --
Russell Barrans
Chief Commercial Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

12400 High Bluff Dr Ste 600
SAN DIEGO   CA   92130-3077

Phone: +1858.5501900

Evofem Biosciences Inc, formerly Neothetics, Inc., is a clinical-stage specialty biopharmaceutical company. The Company develops products to address unmet needs in women's sexual and reproductive health. The Company’s product Amphora, is a Multipurpose Vaginal pH Regulator (MVP-R) designed to regulate vaginal pH to within the normal range of 3.5 to 4.5 even in the presence of semen. This maintains an acidic environment which is inhospitable to sperm as well as certain viral and bacterial pathogens associated with sexually transmitted infections. Amphora is used to prevent urogenital chlamydia and gonorrhea in women. The Company is in the second Phase III clinical trial of Amphora for prevention of pregnancy (AMP002). The Company is currently designing a Phase IIb trial for its second product candidate, a MVP-R to reduce the recurrence of bacterial vaginosis.

SPONSORED STORIES